Amendment

U.S. Serial No. 09/435,992

Atty Reference: 037003-0275478

TECHCENTER TOOKED STORY IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION OF

Vabil Hanna et al.

Group Art Unit: 1644

Application Serial No. 09/435,992

Examiner: P. Gambel

Filed: November 8, 1999

Title: Treatment of B Cell Malignancies Using Anti-CD40L Antibodies in Combina

WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND RADIOTHERAPY

REPLY PURSUANT TO 37 C.F.R. §1.111

Hon. Commissioner of Patents Washington, D.C. 20231

Sir:

In response to the Official Action [non-final rejection] mailed November 12, 2001. Kindly cancel all the current claims and introduce the following additional claims directed to the elected subject matter

In the Claims:

A method of treating a B cell malignancy comprising administering separately or in --60. combination a therapeutically effective amount off:

- an anti-CD20 antibody or fragment thereof; and (i)
- an anti-CD40L antibody or fragment thereof. (ii)
- The method of claim 60 wherein the B cell malignancy is a B cell leukemia. 61.
- 62. The method of claim 60 wherein the B cell malignancy is a B cell lymphoma.
- The method of claim 62 wherein said lymphoma is selected from the group 63. consisting of: small lymphocytic, follicular and predominantly small cleaved cell, follicular and mixed small cleaved and large cell type, follicular and predominantly large cell type, diffuse small cleaved cell, diffuse mixed small and large cell, diffuse large cell, large cell immunoblastic, lymphoblastic, small non-cleaved Burkitt's and non-Burkitt's type, AIDSrelated lymphomas, angioimmunoblastic lymphadenopathy, mantle cell lymphoma, and monocytoid B-cell lymphoma.